Suven's third molecule enters clinical trial phase

New chemical entity is a potential drug for treatment of cognitive dysfunction linked with Alzheimer's and other dementias

Suven Life Sciences today said that their third new chemical entity (NCE) SUVN-D4010 has commenced phase-1 clinical trial in the US.

The NCE is a potential drug for treatment of cognitive dysfunction associated with Alzheimer's disease and other dementia.

"We are very pleased that the third compound from our pipeline of molecules in CNS has moved into a clinical trial that is being developed for cognitive disorders in Alzheimer's and Schizophrenia, a high unmet medical need which has huge market potential globally," Venkat Jasti, CEO of Suven said in a statement.

 

Hyderabad-based Suven Life Sciences is a biopharmaceutical company focused on discovering, developing and commercialising novel pharmaceutical products.

Suven has three clinical stage compounds including a phase-2 initiated candidate.